.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,309,124

« Back to Dashboard

Claims for Patent: 8,309,124

Title:Delayed release tablet with defined core geometry
Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
Inventor(s): Vergnault; Guy (Kembs, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee: Jagotec AG (Muttenz, CH)
Application Number:13/424,069
Patent Claims: 1. A method of administering a glucocorticosteroid active substance selected from prednisone, prednisolone, and methylprednisolone to a patient in need thereof comprising administering to the patient a dosage form comprising a core and a coating surrounding the core, wherein the core comprises the glucocorticosteroid active substance and further comprises at least one disintegrating agent that, upon exposure to aqueous media, provides a force to rupture the coating, wherein the coating comprises at least one insoluble or poorly water soluble hydrophobic material such that the glucocorticosteroid active substance is released from the core as a result of the rupturing of the coating and not as a result of the glucocorticosteroid active substance diffusing through the coating, provided that the coating does not include an insoluble or poorly water soluble hydrophobic material that is a polymer, and wherein the coating ruptures upon immersion in an aqueous medium, regardless of pH of the aqueous medium, after a period of between about 2 to about 6 hours to release the glucocorticosteroid active substance, and provided that the dosage form does not comprise a further enteric coating.

2. The method according to claim 1, wherein the dosage form comprises 1 mg prednisone.

3. The method according to claim 1, wherein the dosage form comprises 5 mg prednisone.

4. The method according to claim 1, wherein the coating does not include a disintegrating agent.

5. The method according to claim 1, wherein the dosage form releases at least 80% of the glucocorticosteroid active substance after 4.5 hours.

6. The method according to claim 1, wherein the dosage form releases about 100% of the glucocorticosteroid active substance after 5 hours.

7. The method according to claim 1, wherein, in vivo, the release of the glucocorticosteroid active substance from the dosage form is independent of the effects of food.

8. A method of treating rheumatoid arthritis in a patient in need thereof comprising administering to the patient a dosage form comprising a core and a coating surrounding the core, wherein the core comprises the glucocorticosteroid active substance and further comprises at least one disintegrating agent that, upon exposure to aqueous media, provides a force to rupture the coating, wherein the coating comprises at least one insoluble or poorly water soluble hydrophobic material such that the glucocorticosteroid active substance is released from the core as a result of the rupturing of the coating and not as a result of the glucocorticosteroid active substance diffusing through the coating, provided that the coating does not include an insoluble or poorly water soluble hydrophobic material that is a polymer, and wherein the coating ruptures upon immersion in an aqueous medium, regardless of pH of the aqueous medium, after a period of between about 2 to about 6 hours to release the glucocorticosteroid active substance, and provided that the dosage form does not comprise a further enteric coating.

9. The method according to claim 8, wherein the dosage form comprises 1 mg prednisone.

10. The method according to claim 8, wherein the dosage form comprises 5 mg prednisone.

11. The method according to claim 8, wherein the coating does not include a disintegrating agent.

12. The method according to claim 8, wherein the dosage form releases at least 80% of the glucocorticosteroid active substance after 4.5 hours.

13. The method according to claim 8, wherein the dosage form releases about 100% of the glucocorticosteroid active substance after 5 hours.

14. The method according to claim 8, wherein, in vivo, the release of the glucocorticosteroid active substance from the dosage form is independent of the effects of food.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc